Sermorelin vs CJC-1295: Duration and chemical changes
Short-lived native GHRH(1-29) gave chemists a problem to work on. Changing the molecule changed how long its signal could be sustained.
Native GHRH(1-29)
Sermorelin has a plasma half-life of about 10-12 minutes after intravenous administration, yet GH stayed elevated for about 3 hours in the pharmacokinetic study. That pair of times is more informative than “short acting” alone. The timing figure places the two measurements beside one another.
This seeming mismatch is, to me, one of the best facts in the file. It is exactly what an upstream signal allows: the administered peptide and the gland’s response have different time courses. It also means a claim about “how long it lasts” needs to name the thing being measured.
D-Ala2 and slower clearance
Campbell’s healthy-men study incorporated D-Ala2 into GHRH(1-29)-NH2 and found a longer half-life with reduced metabolic clearance. A small substitution affected how the body handled the peptide. The PEGylation review discusses another approach to prolonging GHRH-analogue action by adding polyethylene glycol.
These experiments make the chemistry worth lingering over. A modified fragment can preserve an intended activity while changing exposure. Each change also creates a new entry to investigate for tolerability and clinical effects.
Albumin attachment in CJC-1295
The long-acting CJC-1295 analogue uses DAC technology, which enables binding to albumin, a protein circulating in blood. That attachment slows removal. In healthy adults, Teichman’s clinical study found prolonged GH and IGF-1 stimulation over days after single subcutaneous doses.
This is the CJC-1295 studied in the cited long-acting record. The chemical equivalence of similarly named preparations deserves scrutiny before carrying that result across. The duration claim depends on the molecular form that was actually tested.
What prolonged hormone elevation establishes
The CJC-1295 result establishes prolonged stimulation in the healthy adults studied. The older-men sermorelin result establishes increased GH and IGF-1 across 14 days of treatment. These separate experiments supply useful information about exposure and response. They leave a direct clinical ranking unresolved.
The comparison I care about would measure meaningful function and unwanted effects over adequate follow-up, then establish whether longer action helped. A prolonged blood signal by itself cannot settle that judgment. The aging editorial’s caution is relevant whichever duration sounds more convenient.
The brief signal in diagnostic testing
A short stimulus had a practical role in checking whether the pituitary could release GH. The pediatric sermorelin review describes its diagnostic and treatment history. Following the US product’s commercial withdrawal in 2008, Yuen and colleagues discussed the absence of available GHRH and alternative stimulation tests.
This diagnostic chapter deserves more attention, to my mind. Rapid disappearance can be perfectly compatible with a useful diagnostic question. Longer action earns no automatic gold star from me; its value depends on the experiment’s purpose.